News | Thrombectomy Devices | January 08, 2021

FDA Clears Inari Medical FlowTriever System for Treatment of Right Atrial Clot in Transit

510(k) clearance allows retrieval of life-threatening DVT thrombus that has migrated to the heart

The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 

The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 


January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium.

FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 

CIT is a life-threatening condition which occurs when a deep vein thrombosis (DVT) breaks loose and embolizes to the right heart. 25,000 patients are diagnosed with right atrial CIT in the United States annually, and the condition is associated with a mortality rate of over 80 percent if left untreated. 

Interventional cardiologists Gautam Kumar, M.D., Emory, and Rajesh Sachdeva, M.D., Morehouse School of Medicine, recently co-authored a case series on the successful FlowTriever right atrial CIT experience they had, it was published in Catheterization and Cardiovascular Intervention, the official journal of the Society for Cardiovascular Angiography and Interventions (SCAI).[1] 

“Right atrial CIT is a serious condition requiring urgent intervention, yet no single best treatment modality has been established,” Kumar said. “Intervention has traditionally exposed critically ill patients to the risks of open-heart surgery or thrombolytic drugs, or required the setup of complex bypass circuits by specialized perfusion staff in an operating room under general anesthesia. FlowTriever offers an exciting new treatment option to safely remove clot from the right atrium in a short, single session procedure without general anesthesia while avoiding the bleeding risks of thrombolytics.”

“This expanded indication for FlowTriever is the latest testament to Inari’s comprehensive and long-term commitment to the care of venous thrombo-embolism (VTE) patients,” said Bill Hoffman, Inari CEO. “We remain committed to revolutionizing VTE treatment with devices that remove large clot volume from large vessels, now including within the heart, while completely eliminating lytics and their consequent cost, ICU stay, and bleeding complications.”

Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism and clot in transit in the right atrium.
 

Reference:

1. Isha Verma, Eric Y Chang, Gautam Kumar, Rajesh Sachdeva. Catheter directed embolectomy of right atrial clot in transit ‐ A case series. Catheterization and Cardiovascular Intervention. First published online 23 November 2020. https://doi.org/10.1002/ccd.29391

 

 

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now